Ysios Capital
Ysios Capital is a leading life sciences investor focused on financing highly innovative biotech companies worldwide. The firm provides resources to develop novel therapies for indications with high unmet medical needs, aiming to have a positive impact on patients and society. With a global outlook and proven performance, Ysios Capital manages over €400 million in assets and has invested in 40 companies, bringing 19 products to market and having over 70 products at the clinical stage.
Industries
N/A
Nr. of Employees
small (1-50)
Ysios Capital
Carrer Baldiri i Reixac 10, 08028 Barcelona, Spain
Portfolio
Adcendo is a biotech company developing novel targeted anti-cancer therapies based on antibody-drug conjugates (ADCs).
#Biotechnology
Anaconda Biomed is among the world’s most innovative early-stage medical technology companies.
#Medical Technology
Aura Biosciences is applying nanotechnology to the fight against cancer with its novel viral nanoparticle technology.
#Biotechnology
BioVex was focused on the development and commercialization of biological treatments for cancer and infectious disease using oncolytic viruses.
#Biotechnology
CorWave is developing next-generation blood pumps for heart failure patients.
#Medical Technology
Cytoki Pharma is engaged in the development of protein drugs for diseases characterized by epithelial injury.
#Biotechnology
Adcendo is a biotech company developing novel targeted anti-cancer therapies based on antibody-drug conjugates (ADCs).
#Biotechnology
Anaconda Biomed is among the world’s most innovative early-stage medical technology companies.
#Medical Technology
Aura Biosciences is applying nanotechnology to the fight against cancer with its novel viral nanoparticle technology.
#Biotechnology
BioVex was focused on the development and commercialization of biological treatments for cancer and infectious disease using oncolytic viruses.
#Biotechnology
CorWave is developing next-generation blood pumps for heart failure patients.
#Medical Technology
Cytoki Pharma is engaged in the development of protein drugs for diseases characterized by epithelial injury.
#Biotechnology